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AURICULAR TRANSCUTANEOUS VAGAL NERVE STIMULATION IN THE 
TREATMENT OF ALZHEIMER’S DISEASE 
KENDALL LENORE MEHINAGIĆ 
ABSTRACT 
Alzheimer’s disease is the most common cause of dementia worldwide. As the 
disease course progresses, it can be debilitating to the patient and provide a large burden 
for their families and caregivers alike. As our population ages, it more important than 
ever to find safe and efficacious strategies to combat the cognitive effects of Alzheimer’s 
disease. While there have been many recent advances surrounding early identification of 
the disease including the use of PET imaging with specific targeted ligands or CSF 
analysis for biomarkers, there has been less progress in the development of disease 
modifying therapies to halt or reverse the symptoms.  
Vagus nerve stimulation has been a standard in therapy for drug-resistant epilepsy 
and depression for many years. It has been proven to be effective and has led to drastic 
improvement in many patients’ lives whose diseases were refractory to standard 
medications.  There is evidence that stimulation of the vagal nerve leads to a physiologic 
response that also supports long term potentiation of memory within the hippocampus, 
though trials have been limited by sample size in the past due to the necessity of surgical 
implantation of the vagal nerve stimulator device. The recent development of non-
invasive vagal nerve stimulation removes this limitation. This non-invasive strategy takes 
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advantage of the auricular branch of the vagus nerve innervation of the ear to access the 
vagal pathway.  
The following work includes a proposal for a randomized control study to 
investigate the cognitive benefits of non-invasive vagal nerve stimulation of the auricular 
branch of the vagus nerve in a cohort of patients with MCI due to Alzheimer’s disease. 
This trial is planned for patients of neurology or gerontology practices associated with 
Boston Medical Center, Massachusetts General Hospital, Beth Israel Hospital, and 
Brigham and Women’s Hospital. Outcomes of this study will be the change in Mini-
Mental State Examination (MMSE) and Alzheimer’s Disease Assessment Scale-cognitive 
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Alzheimer’s disease (AD) is one of the leading causes of morbidity and mortality 
in the elderly population of the United States and the most common cause of dementia 
worldwide.2 It is a progressive neurodegenerative disease beginning with mild cognitive 
impairment and progressing to dementia with an estimated survival of 3 to 9 years 
following diagnosis.3 Because of the high mortality and morbidity associated with AD, 
this diagnosis has heavy implications for both the patient themselves, as well as for their 
family and caregivers. In 2019 alone, caregivers were estimated to have provided 18.5 
billion hours of care for patients with Alzheimer’s disease and other dementias.2 While 
there are reversible risk factors associated with AD, the most significant risk factor is 
increasing age.4 With a growing aging population, Alzheimer’s disease is only going to 
become more prevalent. Despite ongoing research efforts, available treatment options for 
Alzheimer’s disease are limited to medications that do not reverse or cure the cognitive 
effects. At most, they are a symptomatic treatment that works in a limited population to 
slow the unavoidable functional decline and are only effective early on in the disease.5  
Vagal nerve stimulation (VNS) has been approved by the U.S. Food and Drug 
Administration (FDA) for treatment of both drug resistant epilepsy as well as depression. 
It has also shown early promise in many other diseases processes, including Alzheimer’s 
disease.6 Until recently, use of VNS technology necessitated surgical placement, in which 
a wire with electrodes would be wound around the vagal nerve at the left carotid bundle, 
a generator would be placed in the subclavian region, and a line would be tunneled to 
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connect the two.6 While side effects of the stimulator itself are mild, investigation with 
this device inevitably included both the risk and cost of surgery. For this reason, studies 
on the cognitive effects of invasive VNS (iVNS) have previously been limited to trials 
including patients with previously implanted devices for the aforementioned disorders. 
However, technological advances have resulted in the development of a new non-
invasive technique allowing transcutaneous activation the afferent branches of the vagal 
nerve. This has eliminated the need for surgery and opened up new possibilities for 
clinical trials investigating the use of non-invasive transcutaneous vagal nerve stimulation 
(tVNS) in a larger study population for the treatment of many different diseases 
processes, including Alzheimer’s disease.  
 
Statement of the Problem 
Despite a multitude of studies into the treatment of Alzheimer’s disease, current 
options have limited efficacy.7 With an increasing elderly population and prevalence of 
Alzheimer’s disease, it is imperative that a safe and more effective treatment be found. 
Clinical trials using iVNS for treatment of other disease processes have shown influence 
in cognitive improvement.8 9 The recent development of non-invasive transcutaneous 
vagal nerve stimulation (tVNS) affords an opportunity to safely test the cognitive effects 
of VNS without the need for surgery. This proposed study take advantage of this to 
develop a large-scale randomized control study to act as a base for future investigations 





Activation of the vagus nerve through auricular transcutaneous stimulation in patients 
recently diagnosed with mild cognitive impairment due to Alzheimer’s disease will result 
in slowing or reversal of cognitive decline as illustrated by less change in the Mini-
Mental State Examination (MMSE) and Alzheimer’s Disease Assessment Scale-cognitive 
subscale (ADAS-cog) score after a 2-year treatment period when compared to patients 
recently diagnosed with MCI due to Alzheimer’s disease receiving standard treatment.  
 
Objectives and specific aims 
The goal of this work is to propose a study design to assess the efficacy in slowing of 
cognitive decline in patients with MCI due to AD using non-invasive auricular 
transcutaneous vagal nerve stimulation. Specifically, this study aims to: 
• Investigate the effect of transcutaneous auricular VNS on MMSE and ADAS-cog 
performance over the course of 2 years in patients with MCI due to AD.  
• Show that stimulation of the vagus nerve using transcutaneous auricular VNS is 
more effective than currently approved treatment options.  
• Further investigate side effects of transcutaneous auricular vagal nerve 




REVIEW OF THE LITERATURE 
Background 
Alzheimer’s disease effects an estimated 1 in 14 people over the age of 65 in the 
United States.2 The most common symptom of Alzheimer’s disease is memory 
impairment; however, other cognitive domains may be affected as well. This may lead to 
symptoms including behavioral changes, sleep disturbance, language deficits, 
visuospatial impairment, or impairment in executive functioning.10 These symptoms are 
revealed and tracked by clinicians through mental status examinations including the 
Montreal Cognitive Assessment (MoCA) and the mini-mental status exam (MMSE). 
Progression of Alzheimer’s disease follows a spectrum from normal cognition to the 
advanced cognitive impairment seen in dementia. In 2011, the National Institute for 
Aging (NIA) and the Alzheimer’s Association developed new diagnostic criteria for AD 
to better represent the spectrum of disease, breaking the diagnosis into different phases. 
Prior to experiencing symptoms, a patient may be diagnosed with preclinical AD if they 
have evidence of biomarkers of AD in the absence of symptoms. The first detection of 
cognitive decline on either history or mental status evaluation is diagnosed as minimal 
cognitive impairment (MCI) due to AD. Finally, progression in inability to perform 
activities of daily living (ADL) is labeled as dementia due to AD.11,12 This differentiation 
was made to further delineate early points in the disease at which future treatments may 
prove to be effective prior to onset of irreversible neuronal death.  
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The American Academy of Neurology (AAN) published a practice guideline 
update in 2018 on MCI. This showed incidence by age group (Figure 1) that illustrates 
the high prevalence of MCI with increased age.  
 
Age Group Prevalence 
60-64 years  6.7% 
65-69 years 8.4%  
70-74 years 10.1% 
80-84 years 25.2%  
Table 1: MCI prevalence by age group (Adapted from Peterson 2018)1 
It is important to note that pre-clinical AD and MCI due to AD may not lead to 
development of Alzheimer’s disease or dementia within the patient’s lifetime in all cases. 
However, the AAN found that individuals with MCI over the age of 65 had a relative risk 
of 3.3 for the development of AD dementia compared to age matched individuals without 
MCI. In the case of AD, progression from MCI would show a decline in memory 
functioning typically following the pattern of: early on affecting anterograde episodic 
memory and later in the disease process showing a decline in semantic memory and 
immediate recall.13  
 
Diagnosis 
Clinically, the diagnosis of MCI due to AD and AD dementia are based off scores on 
mental status examinations, as well as from the subjective history told by the patient and 
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those who know them.5 One of the most common examination tests used is the Mini-
Mental State Examination (MMSE) due to its focus on early deficits found in AD. This 
exam includes items addressing orientation, memory, attention and concentration, 
language, and visuospatial function and is scored out of 30 points.14 It has been used to 
model decline in cognitive status in patients with subjective cognitive complaints in many 
diseases, including AD.15 Advantages of the MMSE include the ability to test multiple 
cognitive domains at once, ease of use, absence of the need for additional resources, and 
easy replication between observers, while disadvantages include limited sensitivity and 
heterogenicity of results across demographics.14 Another cognitive exam, the Alzheimer 
Disease Assessment Scale-Cognitive Subscale (ADAS-cog) is more specific to AD and 
has also been commonly used in trials. This is a 13-question exam that assesses memory, 
language, praxis, constructive ability, and orientation. The established cutoff points for 
this exam is >9 points for MCI and >12 points for AD.16  
Along with neurologic testing, diagnosis must also exclude other causes of 
dementia, such as vascular dementia or Lewy Body dementia, and other causes of 
cognitive impairment, such as medication effects, sleep impairment, thyroid 
dysregulation, or depression.1 A definitive diagnosis can only be made post-mortem upon 
histopathologic examination of the brain tissue. Studies comparing post-mortem analysis 
and in vivo diagnosis has found that a purely clinical diagnoses has a sensitivity of 80% 
and specificity of 70%.17  Recent research has sought to narrow the precision in diagnosis 
of Alzheimer’s disease by in vivo measurements of neuropathology, including 
specialized Positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) 
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analysis.5 While these technologies have been found to be highly sensitive and specific, 
they are still being investigated for use outside of clinical trials. 
Though not yet a part of routine clinical practice, in anticipation of the use of CSF 
analysis for the diagnosis of forms of AD, the Alzheimer’s Association published 
acceptable use criteria for lumbar puncture testing in 2018. A number of specific 
indications were identified; however, the overarching idea was that CSF analysis would 
be helpful in the diagnosis of AD pathology in patients with an unclear diagnosis or 
persistent cognitive decline in the absence of another identified cause. After analysis of 
multiple studies, it was reported that CSF analysis for Aβ42, t-tau, and p-tau181 has a 
sensitivity of 90% and specificity of 85% for diagnosis of AD pathology when evaluated 
by post-mortem amyloid PET imaging.17 The increased diagnostic confidence with use of 
CSF biomarker identification holds promise for patients in the future to have a more 
definitive diagnosis earlier in the disease. This would provide more time for advanced 
care planning and lifestyle modifications, as well as possible use of targeted therapies to 
halt or slow the development of neuropathologic process prior to the onset of irreversible 
neuronal death.   
 
Pathophysiology 
Alzheimer’s disease has two major neuropathological findings, amyloid plaques 
and neurofibrillary tangles.7 Amyloid plaques occur with overproduction and decreased 
clearance of amyloid beta protein peptides. Amyloid beta protein peptides are a fragment 
of the extracellular amyloid precursor protein that arises from cleavage by specific 
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secretase enzymes.10 Normal cleavage of amyloid precursor protein is performed by 
alpha and gamma secretase enzymes, leading to a cleavage product that is soluble and 
easily cleared. Cleavage with beta and gamma secretase enzymes, however, produces a 
cleavage product that favors aggregation,10 disrupting connectivity and inducing synaptic 
dysfunction and neuronal death, and ultimately leading to cognitive decline.18 This 
aggregation between neurons has been noted to occur up to 10 years prior to symptom 
onset.11 
The second most common pathology found in Alzheimer’s disease is 
neurofibrillary tangles. This specific pathology occurs due to intracellular 
hyperphosphorylation of the microtubule stabilization protein Tau. In turn, this decreases 
the tubulin binding activity of Tau and leads to self-polymerization into what is known as 
“tangles”. The noted decrease in tubulin binding capacity also leads to collapse of the 
intracellular microtubule network, a crucial component of cell homeostasis through 
protein transport and in maintaining cell structure. Ultimately, these changes lead to loss 
of function and apoptosis.19  
Concurrent with synaptic dysfunction and neuronal death induced by amyloid 
plaques and neurofibrillary tangles, inflammation has been identified as a central 
mechanism behind the development of AD.20 The presence of activated microglial cells, 
as well as inflammatory cytokines, was previously treated as a consequence of 
Alzheimer’s pathology but is now thought to be causative.21 There is increasing evidence 
that, while the activity of microglial cells and astrocytes is essential in maintenance and 
regulation of synaptic remodeling, as well as responding to possible infection, sustained 
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activation of these cells can be dangerous for surrounding brain tissue.22 Similar 
inflammatory processes have been found in other neurodegenerative diseases, such as 
Chronic Traumatic Encephalopathy and Parkinson’s Disease, providing further evidence 
to the claim of inflammation leading to neurodegeneration.20  
In post-mortem tissue analyses, these neuropathologic findings have appeared 
early lateral to the hippocampus, then spread to the hippocampus and neocortex.23 This 
occurs simultaneously with cortical atrophy and ventricular dilatation due to loss of 
surrounding tissue.23 This anatomical localization explains the memory impairment and 
cognitive decline seen in AD. 
 
Current treatment options in Alzheimer’s disease 
Due to the multiple pathologies thought to cause cognitive decline in AD, there 
are many different medication targets under investigation for possible treatments.24 Only 
a few medications, however, have shown efficacy thus far and are approved for use in 
AD dementia. There is no accepted pharmacologic treatment for MCI at this time.1 First 
line treatments are cholinesterase inhibitors (CI) including donepezil, galantamine, and 
rivastigmine. The deterioration of cholinergic neurotransmission has been hypothesized 
to play a major role in the cognitive changes seen in AD.24  These medications block the 
breakdown of acetylcholine, leaving a higher concentration available for action within the 
synapse.25 Studies have shown modest benefit in cognition and functionality in activities 
of daily living with use of CI early in AD. Side effects of the medications include 
bradycardia and syncope, leading to recommendation for discontinuation of medication 
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after a trial period if benefit is not seen.25 In patients with moderate to severe AD,  the 
next available treatment option is the NMDA antagonist and dopamine agonist 
memantine with similar limitations in results and side effects.26 Other treatment options 
include fish oil, which has been led to some improvement in memory in patients with 
MCI in trials.27 28 There are also positive effects in cognition with maintaining a 
Mediterranean Diet29, as well as with regular exercise30, with both lifestyle modifications 
recommended for MCI and AD dementia.   
Treatment options are also available for the non-cognitive symptoms of AD 
including behavioral and psychologic manifestations. These options include SSRIs, 
SNRIs, and anti-psychotics. Such symptoms can occur in all stages of cognitive 
impairment and are known to progress with the disease. These symptoms also greatly 
increase the burden on caretakers.7 
These medications and lifestyle interventions may improve memory and alertness 
in patients with AD or lower the risk of development of the disease, however, there is no 
current disease modifying treatment available that extends survival or overall progression 
of neurodegeneration.5 
 
The vagus nerve and vagal stimulation 
The tenth cranial nerve, known as the vagus, is a mixed autonomic nerve 
consisting of both afferent and efferent sensory fibers. It originates in the medulla 
oblangata then exits the brain stem following the carotid artery and esophagus before 
branching extensively to innervate viscera, including but not limited to the lungs, heart, 
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esophagus, and gut.6 While the vagal nerve is the major parasympathetic efferent to the 
viscera, 80% of the vagal fibers are afferent and act to relay visceral information to the 
CNS. The majority of these afferent fibers then interface with the central nervous system 
at the nucleus of the solitary tract (NST) prior to projecting to higher centers, one of 
which includes the locus coeruleus. This area is the main source of norepinephrine for the 
hippocampus, amygdala, thalamus, hypothalamus, dorsal raphe nuclei, cerebellum, and 
cerebral cortex.31 Vagal nerve stimulation (VNS) as a therapeutic technique takes 
advantage of this pathway. 
 The first vagal nerve stimulator was implanted in 1988 and was approved by the 
FDA in 1997 for treatment of medication refractory partial onset seizures. It has been 
shown to reduce seizure activity by 50% after 2-3 years of use in patients who were 
otherwise treatment refractory.6  Further studies of VNS in epilepsy revealed significant 
mood improvement, which has since led to expansion of the use of VNS to include the 
treatment of chronic or recurrent depression; FDA approved its use for this indication in 
2005.32 In one study it was found that 53.1% of participants reached a 50% reduction in 
their depressive symptoms and 38.9% reached full remission of depressive symptoms 
with VNS.32  While there is consensus on the positive effects of VNS in the treatment of 
epilepsy and depression, alternative uses for this therapy have been proposed due to the 
extensive innervation and biological action of the vagus nerve. This list includes migraine 
headache, rheumatoid arthritis, irritable bowel syndrome, anxiety disorder, and 




While the mechanism of VNS effect is still under investigation, it is hypothesized 
that stimulation of the vagal nerve or its afferent pathways leads to release of 
norepinephrine from the locus coeruleus, which is known to supply structures important 
in memory consolidation within the medial temporal lobe and limbic areas, specifically 
the hippocampus.34 This hypothesis is substantiated by studies showing iVNS induced 
changes in norepinephrine concentration but no change in other neurotransmitter 
concentration within these areas in rats.34 Further evidence for this proposed mechanism 
is found in a study published in 1998 which found that lesioning the locus coeruleus in 
mice with implanted VNS led to a decrease in the anti-epileptic effects35, indicating that 
the norepinephrine release from the locus coeruleus is necessary for the observed effect 
of VNS on epilepsy. 
Initial studies specific to the cognitive effects of VNS were performed in rats with 
results showing cognitive enhancement in inhibitory avoidance memory after moderate 
intensity stimulation, while higher intensity and sham stimulation showed no significant 
cognitive effects.36 37 These results provide further evidence for the hypothesized 
mechanism, as sham stimulation would not lead to release of norepinephrine from the 
locus coeruleus and high intensity stimulation would lead to release of a concentration of 
norepinephrine high enough to evoke an inhibitory effect. Whether this is the direct cause 
for the noted effects on cognition and memory is yet to be determined. Early studies such 
as these have since led to subsequent trials on the cognitive effects of VNS outlined later 
in this work.  
 
 13 
The vast innervation of the vagal nerve and resultant diversity of possible 
therapeutic use of VNS has led to investigation of alternative applications for VNS 
therapy. Unfortunately, these have been limited by the required surgical implantation.38 
Due to these restraints, early studies in cognitive effects were performed using 
participants with VNS implanted for an alternate diagnosis. Implantation includes 
insertion of a small battery powered pulse generator in the left subclavicular region, 
which is connected subcutaneously to bipolar stimulating electrodes guided around the 
left cervical bundle of the vagus nerve.31 While the right cervical bundle is a viable 
option for VNS electrode placement, there is a concern for arrhythmia as it directly 
innervates the SA node and, thus, placement of electrodes is preferred at the left cervical 
bundle site.6 Once placed, the current, pulse width, and frequency parameters are initially 
programmed by the physician or device representative with subsequent control left to the 
patient to allow alterations after extensive education.31 The most common side effects of 
VNS include dysphonia, hoarse voice, and cough due to proximity to the recurrent 
laryngeal nerve.39 Alongside these mild side effects, however, comes the inherent risk of 
surgery including bleeding, specifically while working close to major vessels including 
the carotid artery and jugular vein, infection, and the risk associated with anesthesia.40 
These risks must be explained to potential patients, as well as the risk that they may be a 
non-responder. A review published in 2017 found that only 60.1% of patients who 
underwent VNS placement for treatment of drug-resistant epilepsy responded to the 
therapy.41 The risks have greatly limited VNS trials, especially those aimed at 
Alzheimer’s disease, as the elderly population most at risk for AD is also a population 
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Recent advances in technology have led to the development of non-invasive 
methods of vagal nerve stimulation that address these limitations. Transcutaneous vagal 
nerve stimulation (tVNS) appears in two different forms: cervical transcutaneous 
stimulation (ctVNS) and auricular transcutaneous stimulation (atVNS).43 While studies 
support the use of both, auricular transcutaneous vagal nerve stimulation has appeared in 
more studies and has been found to be more advantageous in ease of use for patients and 
is the form that will be addressed throughout this paper.44  
The auricular branch of the vagus nerve innervates parts the human ear, as proven 
in an extensive cadaver study which showed that the tragus and cymba conchae are the 
regions with the highest concentration of vagal projections.45 While both regions are 
possible targets for transcutaneous stimulation, autonomic biologic activity of stimulation 
at the tragus with known parameters has led to its use as the main target for atVNS.46 
Subsequent studies using fMRI concurrent with atVNS have shown that stimulation at the 
tragus with atVNS leads to activation of the higher centers similar to that achieved using 
invasive VNS (iVNS).40 Studies on the safety and tolerability of atVNS have reported 
local skin irritation and headache as possible side effects.47  
This shows a substantial advantage over the concerns for surgical risks when 
using iVNS and could lead to its use in identification of potential responders to VNS 
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prior to implantation of iVNS or replacement of the use of iVNS completely should 
evidence show comparable results. Currently, more research is needed in this area.  
 
Existing research 
In 1999, Clark et al. found verbal memory improvement in 10 patients with 
previously implanted iVNS for treatment of refractory epilepsy. The study analyzed 
performance on word memory tests in the participants after stimulation was provided at 
different intensities. The study subjects were put in two groups (n=5 on each arm), both 
receiving the same stimulation and subsequent testing, but in different orders. Results 
showed a significant 35.6% improvement in word recognition in both groups after 
stimulation at 0.5mA compared to a 10% decline in word recognition noted after 
stimulation at 0.75-1.5mA and no change seen after sham stimulation. These results not 
only provided evidence to the verbal memory enhancement with VNS but also extended 
previous studies published by this research team showing enhanced inhibitory avoidance 
memory in rats after VNS stimulation at 0.4mA compared to higher intensity or sham 
stimuli.36 Comparison of the studies revealed retained efficacy and similar U shaped 
intensity dependence of the effect of VNS in emotional memory in the rats, as well as 
verbal memory in humans. Advantages of this trial include its blinding, reducing the 
effects of expectation by the examiner. The authors also reported across time variation in 
word recognition, which showed no significant difference in results with repeated testing. 
This prevented persuasion by learned behavior or by cumulative stimulation effects. 
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Limitations of the work included a small sample size, leading to the possibility of 
imbalance between the groups or false conclusions.  
 A study performed by Ghacibeh et al. in 2006 aimed to specify the stage of 
memory affected by VNS, consolidation or retrieval. This was a within subject double-
blind study of ten participants who underwent placement of VNS for treatment of 
refractory epilepsy three months prior.9 Sessions included two phases using the Hopkins 
Verbal Learning Test. The first was a learning phase, where a list of 12 words were read 
aloud to the participants followed by either true stimulation at 0.5mA (intensity based on 
the Clark et al. study) or sham stimulation at 0.0mA. Subjects then had a 20-minute 
distraction period after which time either true stimulation or sham stimulation was 
administered prior to the retrieval phase, where they first were tested on recall, then 
recognition of the 12 words. Participants each underwent three versions of this procedure. 
One where true stimulation was only administered after the learning phase. The second 
where stimulation was only administered after the recall phase. The third where no 
stimulation (sham) was administered in either the learning nor retrieval phase.  Results 
indicated a significant increase in the primary outcome measurement, the retention index, 
to 81.7 after stimulation in the learning phase compared to trials with no stimulation in 
that phase (average retention index = 67.1, p=0.005). No significant difference was found 
in retention after stimulation in the retrieval phase compared to the learning phase or 
sham. These results suggest that cognitive effects of VNS occur in the learning and 
memory consolidation phase, rather than aiding in memory retrieval. Bias in this study 
was controlled by having stimulation administered by an outside party without influence 
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over other study parameters, blind to participants and examiners. Limitations of this 
study, as in the previous, include a small sample size, which leads to questions of external 
validity and false conclusion.9 
The pilot study of cognitive effects of VNS in patients with Alzheimer’s disease 
was performed by Sjögren et al. in 2002. The study population included 10 patients 
meeting the 1984 National Institute of Neurological and Communicative Disorders and 
Stroke and the Alzheimer’s Disease and related Disorders Association criteria for the 
diagnosis of Alzheimer’s disease; there was no control group.48 Each patient underwent 
surgery to implant a vagal nerve stimulator pulse generator prior to the study. The pulse 
generator was set to deliver a 20Hz frequency signal with pulse width of 500 
microseconds and current of 0.25mA for 30 second intervals with 5-minute pauses. All 
patients followed the same treatment schedule. The primary efficacy parameters were 
measured by changes in the ADAS-cog and MMSE scores over 3 and 6 months of 
treatment. Response was defined as an increase or lack of decrease in these scores. 
ADAS-cog scores indicated a response in 70% of participants after 3 months and 80% of 
participants after 6 months. MMSE scores showed response in 90% of participants over 3 
months with continued response in 70% of participants over 6 months. The study also 
investigated behavioral changes, as well as quality of life changes with treatment, both of 
which were not significantly altered at baseline and did not decline over the study 
period.48 While this study provided evidence of cognition enhancement in patients with 
Alzheimer’s disease, there were a few limitations. First, the study lacked a control group 
leading to the possibility of a random memory fluctuations or placebo effect producing 
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the positive results. It should be noted, however, that the data was qualitatively compared 
to a previous placebo-controlled study which found a median 3 point decline of ADAS-
cog scores in patients with Alzheimer’s disease over a 6 month period.49 A second 
limitation is the small sample size. With only 10 patients it is difficult to determine 
whether these results are externally valid and would hold true in a larger study.   
 
Based on the optimistic findings of the above study and that all patients from the 
initial pilot study continued use of the iVNS with only transient and mild side effects, the 
same team followed the participants over 1 year with the additional recruitment of 7 more 
patients with Alzheimer’s disease.  It was found that after 1 year of iVNS treatment, 
41.2% of patients exhibited a response in the ADAS-cog score, while 70.6% of patients 
were deemed responders according to the MMSE score. Similar limitations existed in this 
study as the previous including small sample size, though increased from the previous 
study, and lack of a control sample. 
Technology has since advanced to include a non-invasive vagal nerve stimulator 
device that allows for further investigation of VNS without the need for surgical 
implantation as in iVNS. Due to the known innervation of the auricle to include the 
afferent auricular branch of the vagus nerve45, several studies attempted to determine 
whether transcutaneous stimulation of the overlying anatomical structure, the tragus, 
would activate the vagal afferent pathway. A single blind crossover study performed in 
2018 by Badran et al. utilized fMRI imaging with concurrent transcutaneous VNS 
stimulation of the tragus in 17 healthy adults. Participants underwent two separate visits 
where they received stimulation with parameters optimized based on previous studies of 
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atVNS.50 The parameters included stimulation at 0.5mA for 60 seconds repeated 3 times 
in 6 minutes directed over the tragus (active) for one session, then over the earlobe 
(sham) during the other. After subtraction of background activation from the earlobe 
fMRI results, stimulation over the tragus led to activation, illustrated by increased BOLD 
response, of the cingulate gyrus, frontal cortex, cerebellum, and right caudate, all areas 
which would be innervated by the vagal afferent pathway40. Though the results showed 
activation of areas parallel to the vagal afferent system, it did not show increased activity 
in the brainstem, as would be expected with full vagal nerve stimulation. The authors 
address this by stating that their method of using a larger visual field makes signal in the 
small area of the locus coeruleus and NTS difficult to interpret. With activation seen in 
other regions of vagal innervation, however, the authors were confident that results of the 
study confirm that vagal afferents are activated through transcutaneous stimulation over 
the tragus.40 
Immediate cognitive response to atVNS in healthy individuals was reported in 
2015 from a single-blind randomized control crossover study by Jacobs et al. In this 
study, thirty participants over the age of 55 with no evidence of cognitive deficits or 
neurologic disease were recruited to undergo testing. They were given a face-name 
associative memory task where participants were shown a number of faces, then after a 
brief time presented with both new and old images, and asked to determine whether they 
had seen the faces before and what the name associated with the face was. Response time 
and correct answers were recorded. Stimulation was provided via an ear clip either over 
the tragus (intervention) or over the ear lobe (sham) with parameters in line with previous 
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literature at 8hz frequency, 5.0mA current, and 200microsecond pulse width. The 
experimental condition was associated with a significantly higher number of correct hits 
(35.1) than the sham (31.46, p=0.048).  No serious or long-lasting side effects were 
reported with the highest incidence in transient headache.42 This study provided the first 
evidence that atVNS enhanced associated memory performance after a single session. 
Limitations to the study included small sample size and use of a crossover model that 
could introduce a learning bias.  
Vagal nerve stimulation has potential in use for many different disease processes 
due to the wide reach of vagal nerve innervation. The large economic and personal 
burden of Alzheimer’s disease has earned it multiple trials using this technology. Each 
new trial provided new promise that stimulation of the vagal nerve may work to enhance 
multiple types of cognition, evidenced in the studies above. The shared limitation 
previously was the need to surgically implant the VNS device, as well as the risks 
associated with the surgery. This made large trials difficult and, thus, the significance of 
results restricted by a small sample size. With the development of non-invasive vagal 
nerve stimulation through atVNS and subsequent efficacy in trials, the limitation of 
surgical intervention has been alleviated. This has made a large randomized control trial 







We will conduct a double-blind randomized control trial comparing the change in MMSE 
and ADAS-cog scores of patients with MCI due to AD after two years treatment with 
atVNS and standard of care versus standard of care alone. The goal of this project is to 
determine whether chronic use of atVNS leads to less impairment in memory and 
cognition when compared with standard treatment.  
After initial recruitment, patients will see their clinician for two baseline appointments at 
one and two months to make necessary adjustments to medications and provide 
instruction on use of the NEMOS device. Each participant will then follow up with their 
clinician at 6-month intervals for repeat cognitive testing using the MMSE and ADAS-
cog. 
 
Study population and sampling 
The study population will include males and females age of 65 or older with diagnosis of 
MCI due to AD in accordance with the NIA and Alzheimer’s Association criteria 
published in 201112, as determined by a neurologist or gerontologist practicing within the 
following hospitals: Boston Medical Center, Massachusetts General Hospital, Beth Israel 
Hospital, and Brigham and Women’s Hospital. Patients will be excluded with diagnosed 
AD dementia, clinically unspecified cognitive impairment, or known secondary causes of 
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cognitive impairment. Only patients with the capacity to consent will be included in this 
study.  
Sample size estimates were calculated using the UCSF Clinical and Translational Science 
Institute sample size calculator. We will need to recruit at least 134 patients for the study 
(control group= 67 and intervention group= 67) assuming an alpha of 0.05, a beta of 0.20, 
and a mean decline in MMSE score in patients with MCI of −1.72 ± 3.51 points in 24 
months. The clinically significant difference in MMSE score from baseline is a 25% 
decline based on previous studies.51 The sample size necessary for similar parameters 
with the ADAS-cog examination would require a total of 132 participants and therefore 
isn’t the outcome measure requiring the largest sample size.52  
With a sample size close to 100, stratified randomization is the preferred method. This 




The NEMOS (Cerbomed, Erlangen, Germany) is a transcutaneous electric stimulator 
device that provides stimulation through electrode contacts positioned to contact at the 
tragus that are connected to a control remote.53 The patients will have control to adjust 





Treatment (or intervention) 
Both groups will receive standard of care, which at this time includes use of 
therapeutic cholinesterase inhibitors and memantine with need and dosing determined by 
the participant’s respective neurologist. Lifestyle changes including restriction to a 
Mediterranean Diet and implementation of an exercise routine may also be implemented 
by their providers independently.   
Both groups will also be fitted for an atVNS device. This will occur at the 
participants one-month appointment, at which time the neurologist and research assistant 
assigned to that site will provide teaching on the use of the device. The device parameters 
will be initially adjusted to a range above the individual’s perception threshold and below 
the individual’s pain threshold.54 The patients will be given access to a device 
representative to contact should these parameters need adjusting throughout the trial 
period. The intervention may begin after this appointment. Patients will be instructed to 
use their atVNS device daily at one-hour intervals for a total of four hours per day.54 The 
device will record percentage of daily use to show compliance. Participants in the 
intervention group who wish to discontinue use of the atVNS will be encouraged to 
remain in follow up. 
The device parameters will be set to 0.5mA current delivered at 25 Hz frequency 
in accordance with previously used methods for the intervention group.40 The control 
group will receive stimulation at 1Hz frequency, which is below the threshold of 




Study variables and measures 
The independent variable in this study is the time course and demographics of our 
population, including age, which will be collected by the research assistant at 
recruitment. The dependent variable will be the change from baseline in MMSE and 
ADAS-cog scores (Appendix). This will be assessed at baseline prior to randomization, 
then at 6-month intervals for the remainder of the 2-year intervention time either by a 
research coordinator or the patient’s clinician.  
 
Recruitment 
Recruitment will occur in the initial 6 months of the trial time period. Possible 
participants will be identified from patients who are being followed in memory clinics, 
geriatric clinics, or outpatient neurology clinics practicing in association with the 
following hospitals: Boston Medical Center, Massachusetts General Hospital, Beth Israel 
Hospital, and Brigham and Women’s Hospital for the diagnosis of MCI due to AD. Once 
a possible participant is identified by their clinician, consent will be obtained from them 
to pass their information to the research coordinator assigned to the affiliated hospital 
who will be available Monday through Friday from 9am-5pm. The research coordinator 
will then recruit and consent the patient for the trial.  
 
Data collection 
Following recruitment, the identified and consented participants will undergo a physical 
and neurologic examination to establish a baseline. Patient demographics will be 
collected from the patient’s clinician after consent and at the time of recruitment.  
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MMSE and ADAS-cog results at each 6-month interval will be collected by a research 
coordinator either after administration themselves or from clinicians after administration 
during follow up visits. Any report of adverse events or side effects in either group will 
also be collected from clinicians.  
 
Data analysis 
Upon completion of collection, all data will be processed by the biostatistician. A 
comparison of means will be reported for the study participants ages as well as a chi-
squared analysis of gender to determine if there was a significant difference in 
characteristics between groups prior to the intervention.  
To analyze the study objective, raw MMSE and ADAS-cog scores as well as the 
change from baseline in MMSE and ADAS-cog scores at each time point (6 months, 12 
months, 18 months, 24 months) will be reported for both the control and intervention 
groups. Then average change in MMSE and ADAS-cog scores at each timepoint will 
then be compared with a student T-test to determine if a significant difference is present.  
Finally, raw data of the incidence of reported side effects in both the control and 
intervention group will be reported. A qualitative comparison between the incidence of 
side effects between the groups will also be included.  Due to the fact that this is a pilot 
study, analysis will be performed per-protocol based on the tVNS units ability to track 
participants use in order to best determine if tVNS leads to a significant benefit. In 
subsequent studies, an intention to treat analysis should be utilized to minimize 
exclusions and reduce bias. 
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Timeline and resources 
Following IRB approval, recruitment will continue for the first 6 months. After 
this, the intervention timeline will last 2 year with data analysis continuing for the 
remaining 6 months. Altogether, the study should be completed in 3 years’ time.  
Neurologists and Gerontologists at participating hospitals (Boston Medical 
Center, Massachusetts General Hospital, Beth Israel Hospital, and Brigham and 
Women’s Hospital) must be informed about this study and agree to participate. Research 
coordinators must be available at participating hospitals M-F 9am-5pm for recruitment 
during the initial 6-month time period and afterward to administer the MMSE and 
ADAS-cog by appointment as necessary. Research coordinators must also be approved 
by the Psychological Assessment Resources (PAR) Board which oversees use of the 
MMSE examination to assure between examiner validity. A NEMOS device 
representative must be available for initial programming, then afterward for patient 
questions or device changes. Finally, a biostatistician must be recruited for statistical 
analysis during the final 6-month period.  
Resources necessary include computer access including EMR access and a shared 
space for 10 people. Access to SAS statistical software for analysis will be necessary. 
Permission for use and access to the necessary number of NEMOS devices will be 
obtained prior to the recruitment phase of the trial. PAR permission for use of the MMSE 




Institutional Review Board 
This study protocol involves research in human subjects therefore it will be submitted to 
the Boston University Medical Campus IRB for ethical approval. Due to the use of a 
medical device outside of its marketed and approved use as well as the performance of a 
lumbar puncture for inclusion in the study, this proposal will necessitate a full board 





The proposed study design would allow for the first trial of non-invasive vagal 
nerve stimulation in patients with Alzheimer’s disease. The hypothesized mechanism of 
cognitive enhancement due to norepinephrine activation within the locus coeruleus has 
been backed by many studies.34,35,8,36,37 For this reason, the necessity of this large 
randomized control study to prove the efficacy of VNS on cognition in a population of 
patients with MCI due to AD cannot be emphasized enough.  
This study design in particular serves this objective well. Use of patients who 
have diagnosed MCI are known to have a relative risk of 3.3 for progression to AD 
dementia compared to healthy individuals13. While this means that some participants may 
not show progression of disease, it represents the population most at risk at the most 
opportune time for intervention, which is prior to the irreversible neuronal death seen in 
the progression of AD. Results of the study would need to be analyzed with this in mind. 
This progression of MMSE and ADAS-cog scores in this study population has been well 
studied, allowing easy comparison of results of this study with previous. While the 
potential for preclinical AD patient testing using CSF biomarker analysis or PET imaging 
results was considered based on the NIA and Alzheimer’s Association segmentation of 
phases of AD55, this would have greatly reduced the available participants, and the 
necessity for a large study volume was taken as a higher priority at this time. In addition, 
there is an overlap between neuropathology of normal aging and AD dementia in early 
stages with more studies necessary to ultimately determine the difference.17 The potential 
 
 29 
for finding a place for VNS in preclinical patients prior to cognitive decline is one that 
should be investigated in the future. 
Use of the both the MMSE and ADAS-cog also provides benefits to this study 
design. The MMSE is a traditionally used exam method of tracking cognition. It has been 
utilized in many studies of AD and possible therapeutics in the past, which lends to easy 
comparison of results from this trial to results of past and future studies. Adding the 
ADAS-cog results allows for repeat testing of cognitive domains, which may serve to 
strengthen noted differences in the control and intervention group by substantiating 
changes seen in one exam should they also be present on the other.  
Use of double blinding of the participant and the clinician or research coordinator 
administering the cognitive testing by using the atVNS in both the control and 
intervention group removes both the possibility of examiner bias. Stratifying the 
randomization by age group as well as the use of a high-power for significance increases 
confidence that a type I or type II error will be avoided. As noted above, the anticipated 
estimate of sample size will be based off the data from use of the MMSE in AD research, 
as the ADAS-cog would allow for a smaller size to reach significance. This also leads to 
a higher power for the results of the ADAS-cog data.  
Anticipated limitations of this study include a potentially wide baseline for the 
study participants since diagnosis of Alzheimer’s disease can occur earlier or later 
depending on the presentation, however, including only participants with the diagnosis of 
MCI due to Alzheimer’s disease should limit this range. Another limitation is the 
sensitivity and specificity of the ADAS-cog and MMSE, which is alleviated for by using 
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both examination methods.  
  
Summary 
It is evident from review of prior literature that further investigation of VNS is 
necessary and warranted. Prior studies on VNS use in AD have been limited by the 
requirement of invasive surgical implantation. To circumvent this, authors have 
performed cognitive testing in patients with implanted devices for other diagnoses. These 
studies were limited by small sample sizes the question of VNS use in our specific 
population remained. The first trial to use human participants undergoing iVNS 
placement for AD was limited greatly by sample size, including only 10 patients and then 
adding an additional 7 for a second publication.48,56  
This is where the non-invasive VNS technique truly lends to innovation in this 
field. By allowing a safe alternative to iVNS, non-invasive atVNS allows this study to 
recruit a large number of patients with MCI due to AD without the increased risk of 
surgery. This is especially significant in our study population, as they are at great risk for 
co-morbidities that may lead to surgical complications. Not only would this study provide 
the first high powered investigation into the cognitive effects of VNS but also would 
continue to strengthen the physiologic hypotheses surrounding this disease. Significant 
effect of this intervention would provide evidence that activation of the vagal afferent 
pathways does halt the memory altering effects of the disease process.  This would not 
only help progress the use of VNS as a therapeutic option for AD but may also aid other 
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studies in the creation of other therapeutic techniques with a similar target. It also may 
serve to aid studies in other diseases of memory dysfunction.   
 
Clinical and/or public health significance 
Alzheimer’s disease is a diagnosis that weighs heavily on both the patient as well 
as on their families and caregivers. It causes a progression from mild cognitive deficits 
and confusion, to difficulty with activities of daily living, and altogether functional 
decline. It is a disease affecting the vulnerable and growing elderly population and is 
estimated to affect 88 million people worldwide by 2050.2 Current treatment options are 
limited in number, efficacy, and side effect profiles. In fact, the first line treatment for 
AD at this time is also associated with a 63% increased hazard of fall.57 It is imperative 
that a safer and more effective treatment be found for this disease.  
 This study may lead to defining that treatment. Non-invasive vagal nerve 
stimulation has a mild side effect profile and reported ease of use.47 VNS has been shown 
in various trials to have cognitive effects and tVNS has been shown to have similar 
efficacy as iVNS. These advantages suggest that atVNS has true potential to be the safe 
and effective treatment scientists have been searching for. This proposed trial would 
serve to validate prior study results and act as a backbone to continue research into this 







MMSE Examination (Folstein, 1975)14  
 1
 




Patient’s Name:         Date:     
 
Instructions: Ask the questions in the order listed. Score one point for each correct 







5  “What is the year?  Season?  Date?  Day of the week?  Month?” 
5  “Where are we now: Sta te?  County?  Town/city?  Hospital?  Floor?” 
3  
The examiner names three unrelated objects clearly and slowly, then 
asks the patient to name all three of them. The patient’s response is 
used for scoring. The examiner repeats them until patient learns all of 
them, if possible. Number of trials: _ __________ 
5  
“I would like you to count backward from 100 by sevens.” (93, 86, 79, 
72, 65, …) Stop after five answers. 
Alternative: “Spell WORLD backwards.” (D-L-R-O-W) 
3  
“Earlier I told you the names of three things. Can  you tell me what those 
were?” 
2  
Show the patient two simple object s, such as a wristwatch and a pencil, 
and ask the patient to name them. 
1  “Repeat the phrase: ‘No ifs, ands, or buts.’” 
3  
“Take the paper in your right hand, fold it in half, and put it on the floor.” 
(The examiner gives the patient a piece of blank paper.) 
1  
“Please read this and do what it says.” (Written instruction is “Close 
your eyes.”) 
1  
“Make up and write a sentence about anything.” (This sentence must 
contain a noun and a verb.) 
1  
“Please copy this picture.” (The examiner gives the patient a  blank 
piece of paper and asks him/her to draw the symbol below. All 10 




30  TOTAL 
(Adapted from Rovner & Folstein, 1987)
Source: www.medicine.uiowa.edu/igec/tools/cognitive/MMSE.pdf Provided by NHCQF, 0106-410
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